Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

(2015) Stefan Zeuzem et al.   ANNALS OF INTERNAL MEDICINE

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

(2015) Christophe Hézode et al.   LANCET

Reduction of MicroRNA 122 Expression in IFNL3 CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C

(2014) E. Estrabaud et al.   JOURNAL OF VIROLOGY

Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity

(2014) Tarik Asselah et al.   LIVER INTERNATIONAL

Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection

(2014) Tarik Asselah et al.   LIVER INTERNATIONAL

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

(2014) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

(2014) Jordan J. Feld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

(2014) Kris V. Kowdley et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

(2014) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir for the treatment of hepatitis C virus

(2013) Tarik Asselah   EXPERT OPINION ON PHARMACOTHERAPY

HCV direct-acting antiviral agents: the best interferon-free combinations

(2013) Raymond Schinazi et al.   LIVER INTERNATIONAL

Faldaprevir and Deleobuvir for HCV Genotype 1 Infection

(2013) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomics and HCV infection: Progression of fibrosis and treatment response

(2012) Emilie Estrabaud et al.   JOURNAL OF HEPATOLOGY

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C

(2011) Tarik Asselah et al.   JOURNAL OF HEPATOLOGY

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

(2011) Tarik Asselah et al.   LIVER INTERNATIONAL

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin

(2009) Michelle Martinot-Peignoux et al.   HEPATOLOGY